U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182409) titled 'Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder' on Sept. 04.
Brief Summary: This study aims to evaluate the efficacy and safety of different monoclonal antibody in the acute phase of neuromyelitis optica spectrum disorder (MAAP-NMO). It will also examine immune-related biomarkers and their relationship with treatment response to provide evidence for optimizing acute-phase therapeutic strategies.
Study Start Date: Oct. 01
Study Type: OBSERVATIONAL
Condition:
NMOSD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: First Affiliated Hospital of Chongqing Medical University
Infor...